TCGA-BH-A1F8-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.540
- INTERFERON_ALPHA_RESPONSE+0.450
- MTORC1_SIGNALING+0.360
- PANCREAS_BETA_CELLS+0.350
- ANDROGEN_RESPONSE+0.330
- E2F_TARGETS+0.320
- INTERFERON_GAMMA_RESPONSE+0.290
- MYC_TARGETS_V1+0.290
- OXIDATIVE_PHOSPHORYLATION+0.290
- G2M_CHECKPOINT+0.250
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.400
- MYOGENESIS-0.350
- TNFA_SIGNALING_VIA_NFKB-0.260
- ALLOGRAFT_REJECTION-0.240
- HEDGEHOG_SIGNALING-0.230
- KRAS_SIGNALING_DN-0.220
- APICAL_JUNCTION-0.210
- APICAL_SURFACE-0.180
- IL6_JAK_STAT3_SIGNALING-0.180
- MYC_TARGETS_V2-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1JT-01A-31R-A13Q-07 | — | B | 0.821 |
| 2 | BS_TXZ7KHTQ | high-grade glioma | — | 0.820 |
| 3 | 9cdb8246-eedc-40e2-b340-52db1edd0838 | — | — | 0.804 |
| 4 | SJEPD031160_D1.RNA-Seq | EPN | EPN Tumor | 0.802 |
| 5 | SRR25617939 | — | B | 0.794 |
| 6 | SRR1797282 | — | cohortSC | 0.789 |
| 7 | cb6e4e0c-6f89-4ea5-a89d-1b0da8cf7fac | — | — | 0.788 |
| 8 | SRR1797281 | — | cohortSC | 0.788 |
| 9 | BS_CZ3ER8DY | EPN | Supratentorial EPN | 0.783 |
| 10 | BS_CZ3ER8DY | Supratentorial Ependymoma | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.540 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |